Sanofi and C4X in $493m licensing deal

UK company C4X Discovery has agreed an exclusive licensing deal with Sanofi worth a potential €414 million ($493 million), which will see the French pharmaceutical company develop anti-inflammatory therapies.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Fed Circ rejects Sanofi’s bid to resurrect Lantus patents

4 January 2022 The US Court of Appeals for the Federal Circuit has rejected several bids from French pharma giant Sanofi to revive claims in its Lantus SoloStar insulin pen patents.

Medtech

PTAB invalidates Sanofi injector patent

1 April 2021 Mylan Pharmaceuticals has succeeded in getting the Patent Trial and Appeal board (PTAB) to invalidate an injector patent held by French pharmaceutical company Sanofi

Biotechnology

The uncertain future of antibody claims

1 April 2021 Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Sanofi and C4X in $493m licensing deal

More on this story

Editor's picks

Editor's picks

More features